Release date: 2015-06-11
In recent days, a circle of friends circulated an article on June 3rd with a note on the road, "Extra size: American company announced that humans have already conquered cancer." Someone asked me if it was true. For such a big headline, the first instinct is to pull the big flag and blow it. For ordinary people, you don't have to be a layman. If you really have a king size like cancer, I fully believe that this information will appear in the headlines of any big and small news media in the world, or else it will insult our IQ. I am not an expert, but I keep track of the medical industry information all the year round. Observers ask me to say a few words, then share some of my knowledge.
Friends of the circle of the United States to overcome cancer articles
The article is about Alnlam Pharmaceuticals' ALN-VSP drug that uses their RNAi technology to organize tumor growth and claims that "this drug may even cure all diseases over time." As I mentioned in my previous article, this company has a leading position in RNAi technology, but I haven't seen, heard, and heard this information about the status of clinical development of new drugs every day. Impression is also a few years ago, Alnylam is indeed very Hype (promotional hype), was pursued for a while. These two years seem to be a lot quieter.
But I am not satisfied with the initial impression of this article. So use Google to search the index of this article. Google gave me a dozen pages of link index. These links lead me to domestic large and small media, regular evening newspapers, professional medical forums, and personal microblogs. This article first appeared in 2010. Although everyone later learned that this article has a large exaggeration of its false elements, it has been circulating since then, and it is still today. On June 5th, the online celebrity "known" Xue Manzi also forwarded this article, and the result was skunk by a group of people.
Such an old and falsely exaggerated article, why is it so popular today? There are hundreds of thousands of people watching it. Thousands of people turned around on Xue Manzi's Weibo, and thousands of people liked it. I have to feel that today's society is morally and immoral, whether it is true or false, entertainment is paramount, and attention is paramount. Although many people know that this is not true, there are always a lot of people who are so happy that they are constantly trying to earn traffic with such eye-catching titles.
While browsing some professional medical forums, I also noticed that many people who follow the post may be cancer patients themselves, or have cancer patients among relatives and friends, so they need to know this information urgently. The needs of these patients are real, and there is a lot of confusion and powerlessness in the face of these mixed information. How to effectively provide a fair and transparent information channel for patients and patients is not only a matter of merit, but also a very big business opportunity. In particular, today's social media big data is prevalent, new technologies can not only be used for entertainment to improve traffic, but also should be used to establish a number of national and international doctors and patients through trains, to put remote high-quality medical information into the local.
I learned a lot about the sharing of information between patients from a group of Stanford doctors. Currently in the United States, there are two Internet medical websites that focus on patient information exchange, patient socialization, and big data sharing: PatientsLikeMe and SmartPatients.
PatientsLikeMe was founded in 2006 by two brothers, James Heywood and Ben Heywood. The story of their creation of this site was very touching. In 1998, James's younger brother, Stephen Haywood, was diagnosed with ALS, a rare condition of the muscular nervous system. The ice bucket challenge of the previous period was to raise money for the disease. After getting this disease, I will slowly lose my athletic ability, but the patient's brain will not be affected, so the consciousness is very clear. Imagine the cruelty of being unable to move with one hand and one finger when you are awake. Because there are very few patients with this disease, few pharmaceutical companies are willing to invest in research and development drugs. So, at that time, my good brother James? Haywood quit his job and concentrated on seeking medical treatment for his younger brother. During the eight years of painstaking treatment, they have accumulated a lot of experience, but the disease has been deteriorating and sad. In this process, they realized the lack of information, so they thought that they could share information with patients in the same situation.
At the time, another rare disease, the chondoma (very rare neurological tumor) foundation was successfully created, and the brothers were encouraged to register and founded the "PatientsLikeMe" website. To date, this site has been dominated by the ALS area at the time and has rapidly expanded into a variety of diseases, including many neurological diseases and orphan diseases. The site currently has hundreds of thousands of users, covering 12 major systems of disease.
The profit model of the "PatientsLikeMe" website is very interesting. They don't charge or advertise, but they have a database that asks patients to submit disease and treatment information anonymously, including medical history, medication, efficacy, side effects, etc., forming a complete medical treatment. recording. Then the website background is analyzed and summarized, and then shared with the same case. In the end, the company sold the information for analysis and analysis to third parties, including drug development companies such as Merck, Novartis and Genentech, which signed large contracts with them.
SmartPatients is a patient online community founded in 2013 by the original google ex-chief health strategist Dr Zeiger. It was originally built for oncology patients to help them learn from each other and support each other through similar conditions. This is similar to PatientsLikeMe. But the difference between it and the PatientsLikeMe is that SmartPatients focus on helping patients interact and communicate emotionally, while PatientLikesMe emphasizes information sharing, in fact, the two are inseparable.
SmartPatients' current profit model is mainly to help medical, health care, and research institutions better understand patients, thus effectively helping to design clinical trials (in the hundreds of millions of clinical trials, feedback on patient information before starting) is essential. Currently they have almost 30 forums, more than 10,000 patients and their family and friends. The most important and hottest discussion is to focus on the treatment experience and help other patients find the best treatment. For some rare diseases, this may be more useful than talking to a doctor.
I am not a doctor. I don't understand this information. I would like to introduce the above information. I hope that people with the heart and ability can build a platform across China and the United States. This can take advantage of American medical resources, combined with high-tech real-time translation, real-time search, and Chinese patients. Use this platform to learn about the latest treatment information in the United States. I believe this is also a good business opportunity for resource integration.
Go back to the "extra large" we said earlier. Although the title has the style of exaggerating the title party, the content still has some real ingredients. But the story did not happen in 2015, but the ASCO Annual Meeting in June 2010 (American Cancer Society Annual Meeting). The 2010 and 2011 ASCO Annual Meetings were the most spectacular two years of Alnylam Pharmaceuticals. At that time, ALN-VSP drugs using this company's RNAi technology seemed to see some effects. But at the same time, after a decade of trials by major pharmaceutical companies such as Novartis, Merck and Roche, it has been found that such drugs are very difficult to deliver correctly and have begun to reduce support for the RNAi product line. Alnylam Pharmaceuticals is based on RNAi technology and continues to develop medicines that rely on many people's hopes. Although I see more hype today, it is hard to say that there will be no breakthrough in the future. Today's Alnylam Pharmaceuticals still has an RNAi-based product line that is still promising, but the ALN-VSP drug is no longer there. As for this "extra large" outside the ASCO annual meeting this year, it is widely spread in the country, I don't know if there are any other purposes.
Alnylam Pharmaceuticals current product development line
It is worth noting that Alnylam Pharmaceuticals licenses the development of ALN-VSP in Greater China to a company called Ascletis Pharmaceuticals. This company is called Hangzhou Songli Bioscience Company (Shifang Pharmaceutical?) in China. The information currently seen on the company's public website shows that ALN-VSP is still in the first phase of the trial.
This company is also regarded as a domestic new biotechnology company, and it has developed in the Greater China region through the introduction of product lines of large foreign companies. Although the introduction of these drugs is not the most advanced, for example, the Danoprevir introduced from Roche in 2013 is very different from the Solvadi and Harvoni of the world's leading Gilead biotechnology company. In the United States, I have not seen the latest developments in Danoprevir, and I have been forced to withdraw from a strong opponent like Vertex. But obviously the ceremonial bioscience company has its own unique perspective. They believe that Roche's hepatitis D drug Danoprevir should be more suitable for the Chinese population. Because they think that China's chronic hepatitis C population is mostly genetic 1a. In March of this year, their second phase trials in Taiwan, Thailand and South Korea showed that after 12 weeks of treatment, the cure rate (SVR12) of patients with type 1 non-cirrhosis in Taiwan reached 94%, and the cure rate of patients with type 1b non-cirrhosis reached 100%. At the annual meeting of the Asia-Pacific Association for the Study of Liver Diseases, together with Gilead's Sofosbuvir and Bristol-Myers Squibb's Beclabuvir, the President of the conference received the special theme report award.
Ascletis Pharmaceuticals (Hangzhou Songli Biosciences) current product development line
Individuals sincerely hope that more and more new drug development companies in the country can be in line with the international frontier in technology, localization in solution, and the development of domestic patients for the benefit of Chinese patients. I also hope that this is a real act of drug development for the benefit of mankind, not just playing capital.
Source: Observer Network
Sand Lance
Sand Lance,Pacific Sand Lance,Sand Lance Fish,Frozen Sand Lance
ZHEJIANG EVERNEW SEAFOOD CO.,LTD , https://www.evernewseafood.com